MCID: PHS001
MIFTS: 40

Phosphorus Metabolism Disease

Categories: Metabolic diseases

Aliases & Classifications for Phosphorus Metabolism Disease

MalaCards integrated aliases for Phosphorus Metabolism Disease:

Name: Phosphorus Metabolism Disease 12 15
Phosphorus Metabolism Disorders 45 74
Disorder of Phosphorus Metabolism 12
Phosphorus Metabolism Disorder 12
Phosphorus Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2485
ICD9CM 36 275.3
MeSH 45 D010760
NCIt 51 C97095
SNOMED-CT 69 87049008
UMLS 74 C0031707

Summaries for Phosphorus Metabolism Disease

MalaCards based summary : Phosphorus Metabolism Disease, also known as phosphorus metabolism disorders, is related to hypophosphatemia and autosomal recessive hypophosphatemic rickets. An important gene associated with Phosphorus Metabolism Disease is FGF23 (Fibroblast Growth Factor 23), and among its related pathways/superpathways are Signaling by FGFR2 and Parathyroid hormone synthesis, secretion and action. The drugs Nicotinamide and Calcium Carbonate have been mentioned in the context of this disorder. Affiliated tissues include kidney and bone, and related phenotypes are growth/size/body region and homeostasis/metabolism

Related Diseases for Phosphorus Metabolism Disease

Diseases related to Phosphorus Metabolism Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Related Disease Score Top Affiliating Genes
1 hypophosphatemia 31.0 FAM20C FGF23 PHEX PTH SLC34A1 SLC34A3
2 autosomal recessive hypophosphatemic rickets 30.5 FGF23 GALNT3 PHEX
3 hypophosphatemic rickets, autosomal dominant 30.3 FGF23 GALNT3 PHEX SLC34A3
4 vitamin d-dependent rickets, type 2a 29.8 CYP27B1 PHEX VDR
5 hypophosphatemic rickets, x-linked dominant 29.8 FGF23 KL PHEX PTH SLC34A1 SLC34A3
6 hyperphosphatemia 29.8 CASR FGF23 GALNT3 GNAS KL PHEX
7 hypophosphatemic rickets with hypercalciuria, hereditary 28.4 CYP27B1 FGF23 GALNT3 KL PHEX PTH
8 tracheal calcification 10.4 FGF23 KL
9 opsismodysplasia 10.3 FGF23 PHEX
10 hereditary hypophosphatemic rickets 10.3 SLC34A1 SLC34A3
11 enthesopathy 10.3 FGF23 PHEX
12 impaired renal function disease 10.3 FGF23 PTH
13 hypocalciuric hypercalcemia, familial, type i 10.2 CASR PTH
14 oncogenic osteomalacia 10.2 FGF23 PHEX PTH
15 hypocalciuric hypercalcemia, familial, type ii 10.2 CASR PTH
16 hypocalciuric hypercalcemia, familial, type iii 10.2 CASR PTH
17 urinary system disease 10.2 FGF23 KL PTH
18 hypoparathyroidism, familial isolated 10.2 CASR PTH
19 tumoral calcinosis, hyperphosphatemic, familial, 1 10.2 FGF23 GALNT3 KL
20 hyperostosis 10.2 FGF23 GALNT3 KL
21 familial isolated hyperparathyroidism 10.2 CASR PTH
22 testicular microlithiasis 10.2 GALNT3 SLC34A2
23 hypothyroidism, congenital, nongoitrous, 1 10.2 GNAS STX16
24 connective tissue benign neoplasm 10.2 GNAS PTH
25 hypophosphatasia, adult 10.1
26 acid phosphatase deficiency 10.1
27 hypophosphatasia, infantile 10.1
28 hypophosphatasia, childhood 10.1
29 hypophosphatasia 10.1
30 prenatal benign hypophosphatasia 10.1
31 familial hypocalciuric hypercalcemia 10.1 CASR PTH
32 hypoparathyroidism 10.1 CASR FGF23 PTH
33 arterial calcification of infancy 10.1 FGF23 PHEX
34 raine syndrome 10.1 FAM20C FGF23
35 pseudopseudohypoparathyroidism 10.1 GNAS PTH STX16
36 pseudohypoparathyroidism 10.1 GNAS PTH STX16
37 spondylosis 10.1 KL PTH VDR
38 pseudohypoparathyroidism, type ib 10.1 GNAS PTH STX16
39 albright's hereditary osteodystrophy 10.1 GNAS STX16
40 familial tumoral calcinosis 10.1 FGF23 GALNT3 KL PHEX
41 calcinosis 10.1 FGF23 GALNT3 KL PHEX
42 osteitis fibrosa 10.0 CASR GNAS PTH
43 multiple endocrine neoplasia, type i 10.0 CASR GNAS PTH
44 metaphyseal chondrodysplasia, jansen type 10.0 FGF23 PTH
45 hypercalcemia, infantile, 1 10.0 CASR PTH VDR
46 hypercalciuria, absorptive, 2 10.0 CASR SLC34A3 VDR
47 parathyroid adenoma 10.0 CASR PTH VDR
48 idiopathic hypercalciuria 9.9 CASR SLC34A3 VDR
49 uremia 9.9 CASR PTH VDR
50 caffey disease 9.9 FAM20C GALNT3

Comorbidity relations with Phosphorus Metabolism Disease via Phenotypic Disease Network (PDN): (show all 14)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Bronchitis
Chronic Kidney Failure Decubitus Ulcer
Deficiency Anemia Heart Disease
Hypertension, Essential Hypothyroidism
Iron Deficiency Anemia Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder

Graphical network of the top 20 diseases related to Phosphorus Metabolism Disease:



Diseases related to Phosphorus Metabolism Disease

Symptoms & Phenotypes for Phosphorus Metabolism Disease

MGI Mouse Phenotypes related to Phosphorus Metabolism Disease:

47 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.36 CASR CYP27B1 FAM20C FGF23 GALNT3 GNAS
2 homeostasis/metabolism MP:0005376 10.3 CASR CYP27B1 FAM20C FGF23 GALNT3 GNAS
3 behavior/neurological MP:0005386 10.23 CASR CYP27B1 FAM20C GNAS KL PHEX
4 endocrine/exocrine gland MP:0005379 10.22 CASR CYP27B1 FAM20C FGF23 GALNT3 GNAS
5 cellular MP:0005384 10.21 CASR CYP27B1 FAM20C GALNT3 GNAS KL
6 digestive/alimentary MP:0005381 10.19 CASR FAM20C FGF23 GALNT3 KL PHEX
7 hematopoietic system MP:0005397 10.18 CASR CYP27B1 FAM20C FGF23 GALNT3 GNAS
8 cardiovascular system MP:0005385 10.17 FGF23 GALNT3 GNAS KL PHEX PTH
9 craniofacial MP:0005382 10.15 CYP27B1 FAM20C GALNT3 GNAS KL PHEX
10 immune system MP:0005387 10.13 CASR CYP27B1 FAM20C FGF23 GALNT3 GNAS
11 limbs/digits/tail MP:0005371 10.02 CYP27B1 FAM20C FGF23 GALNT3 GNAS KL
12 mortality/aging MP:0010768 10.02 CASR FAM20C FGF23 GNAS KL PHEX
13 adipose tissue MP:0005375 9.98 CYP27B1 GNAS KL PHEX STX16
14 integument MP:0010771 9.95 CASR CYP27B1 FGF23 GALNT3 GNAS KL
15 renal/urinary system MP:0005367 9.93 CASR CYP27B1 FAM20C FGF23 GALNT3 GNAS
16 hearing/vestibular/ear MP:0005377 9.89 FAM20C GNAS KL PHEX VDR
17 muscle MP:0005369 9.73 CASR GALNT3 GNAS KL SLC34A1 VDR
18 reproductive system MP:0005389 9.5 CYP27B1 FAM20C FGF23 GALNT3 KL SLC34A1
19 skeleton MP:0005390 9.44 CASR CYP27B1 FAM20C FGF23 GALNT3 GNAS

Drugs & Therapeutics for Phosphorus Metabolism Disease

Drugs for Phosphorus Metabolism Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotinamide Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 98-92-0 936
2
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 471-34-1
3
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68-04-2
4
Sevelamer Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52757-95-6
5
Calcium acetate Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 62-54-4
6
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6, 15438-31-0 23925 27284
7
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 1,Phase 2,Not Applicable 59-67-6 938
8
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-70-2 271
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 59-30-3 6037
10
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 77-92-9 311
11
Calcitriol Approved, Nutraceutical Phase 4,Not Applicable,Early Phase 1 32222-06-3 134070 5280453
12
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 1406-16-2
13
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 50-14-6 5280793
14 Vasodilator Agents Phase 4,Phase 1,Phase 2,Not Applicable
15 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Antimetabolites Phase 4,Phase 1,Phase 2
17 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Nutrients Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
20 Vitamin B Complex Phase 4,Phase 1,Phase 2,Not Applicable
21 Hypolipidemic Agents Phase 4,Phase 1,Phase 2
22 Nicotinic Acids Phase 4,Phase 1,Phase 2,Not Applicable
23 Trace Elements Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
24 Vitamins Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
25 Micronutrients Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
26 Vitamin B9 Phase 4,Phase 1,Phase 2,Not Applicable
27 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Folate Phase 4,Phase 1,Phase 2,Not Applicable
29 Lipid Regulating Agents Phase 4,Phase 1,Phase 2
30 Antacids Phase 4,Phase 3,Phase 2,Not Applicable
31 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Vitamin B3 Phase 4,Phase 1,Phase 2,Not Applicable
33 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1
34 Citrate Phase 4,Phase 3,Phase 2,Phase 1
35 Ferric Compounds Phase 4,Phase 3,Phase 2
36 Chelating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Hematinics Phase 4,Phase 3,Phase 2,Not Applicable
38 Calciferol Phase 4,Phase 3,Not Applicable,Early Phase 1
39 Vasoconstrictor Agents Phase 4,Not Applicable,Early Phase 1
40 Vitamin D2 Phase 4,Phase 3,Not Applicable
41 Ergocalciferols Phase 4,Phase 3,Not Applicable
42
Parathyroid hormone Approved, Investigational Phase 3,Phase 1 9002-64-6
43
Cinacalcet Approved Phase 3,Phase 1,Not Applicable 226256-56-0 156419
44
carbamide peroxide Approved Phase 3 124-43-6
45 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
46 Mitogens Phase 3,Phase 2,Phase 1,Not Applicable
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2,Not Applicable
48 Hormone Antagonists Phase 3,Phase 1,Phase 2,Not Applicable
49 Calcimimetic Agents Phase 3,Phase 1,Not Applicable
50 Bile Acids and Salts Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 168)
# Name Status NCT ID Phase Drugs
1 Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia Unknown status NCT02836184 Phase 4 Nicotinic Acids;Calcium Carbonate
2 A Study of Ferric Citrate to Improve Inflammation and Lipid Levels Unknown status NCT02661295 Phase 4 Ferric Citrate
3 Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients Completed NCT01755078 Phase 4 Sevelamer HCl;Calcium-based phosphate binder
4 Phosphate Kinetic Modeling 2 Completed NCT01252771 Phase 4
5 Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia Recruiting NCT03820518 Phase 4 Calcitriol
6 A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease Recruiting NCT03466983 Phase 4 Iron Isomaltoside;Ferric Carboxymaltose
7 Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis Active, not recruiting NCT03256838 Phase 4 Ferric Citrate
8 Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients Active, not recruiting NCT03079869 Phase 4 Ferric Citrate
9 Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia Enrolling by invitation NCT02237534 Phase 4 Lanthanum carbonate;Calcium Carbonate
10 The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis Not yet recruiting NCT03163576 Phase 4 Niacin;Phosphate Binder
11 Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol Terminated NCT01725113 Phase 4 Calcitriol;Paricalcitol
12 A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia Completed NCT01852682 Phase 3 PA21
13 A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850641 Phase 3 PA21
14 A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850602 Phase 3 PA21;Sevelamer hydrochloride
15 A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01833494 Phase 3 PA21
16 Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study Completed NCT01578200 Phase 3 Lanthanum Carbonate;Calcium Carbonate
17 Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients Completed NCT01518387 Phase 3 Lanthanum Carbonate (BAY77-1931)
18 Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate Completed NCT01514851 Phase 3 Lanthanum carbonate (BAY77-1931);Calcium carbonate
19 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease Completed NCT01503736 Phase 3 ferric citrate;ferric citrate;ferric citrate
20 Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742611 Phase 3 ASP1585
21 A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742585 Phase 3 ASP1585;placebo
22 A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis Completed NCT01057407 Phase 3 ASP1585;Sevelamer hydrochloride
23 A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis Completed NCT01017276 Phase 3 ASP1585
24 Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis Completed NCT00892749 Phase 3 ASP1585
25 EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease) Completed NCT00211978 Phase 3 calcium acetate;placebo
26 Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules Completed NCT02027662 Phase 2, Phase 3 Osvaren Granules;Osvaren film-coated tablets
27 A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis Completed NCT01554982 Phase 3 ferric citrate
28 Long-term Study in Chronic Kidney Disease (Extension From Study 14817) Completed NCT01187628 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931)
29 Study in Chronic Kidney Disease (CKD) Not on Dialysis Completed NCT01110629 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931);Placebo
30 Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients Completed NCT01069692 Phase 3 SBR759A;SBR759A;SBR759A;SBR759A;SBR759A
31 Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00772382 Phase 3 MCI-196
32 An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis Completed NCT00681941 Phase 3 Sevelamer carbonate (Renvela®)
33 A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00542815 Phase 3 MCI-196;Another Phosphate binder (Sevelamer)
34 A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia Completed NCT00506441 Phase 3 MCI-196;Placebo
35 A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia Completed NCT00416520 Phase 3 MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®);Placebo;Another phosphate binder (Sevelamer)
36 An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD) Completed NCT02675998 Phase 3 Tenapanor;Placebo
37 A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis Completed NCT01191255 Phase 3 ferric citrate, ca acetate, sevelamer carbonate, placebo
38 A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease Completed NCT01074125 Phase 3 ferric citrate
39 A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia Completed NCT00542386 Phase 3 MCI-196;Placebo
40 Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) Completed NCT02537431 Phase 3
41 Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH) Completed NCT02526160 Phase 3
42 A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (IDA-04) Completed NCT03238911 Phase 3 Iron isomaltoside (Monofer);Ferric carboxymaltose
43 A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (IDA-05) Completed NCT03237065 Phase 3 Iron Isomaltoside (Monofer);Ferric carboxymaltose
44 Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets Completed NCT00417612 Phase 3 Paricalcitol
45 Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D Completed NCT02492620 Phase 3 Ferric Citrate
46 Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients Completed NCT00975000 Phase 3 Cinacalcet;Placebo
47 Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets Completed NCT01237288 Phase 3 Z-521
48 Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy Recruiting NCT03824587 Phase 2, Phase 3 Tenapanor;Placebo
49 An Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia Recruiting NCT02688764 Phase 3 PA21 (Velphoro®);Calcium Acetate (Phoslyra®)
50 PA21 Safety and Efficacy in Adult Chinese Subjects Recruiting NCT03644264 Phase 3 PA21;sevelamer carbonate

Search NIH Clinical Center for Phosphorus Metabolism Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: phosphorus metabolism disorders

Genetic Tests for Phosphorus Metabolism Disease

Anatomical Context for Phosphorus Metabolism Disease

MalaCards organs/tissues related to Phosphorus Metabolism Disease:

42
Kidney, Bone

Publications for Phosphorus Metabolism Disease

Variations for Phosphorus Metabolism Disease

Expression for Phosphorus Metabolism Disease

Search GEO for disease gene expression data for Phosphorus Metabolism Disease.

Pathways for Phosphorus Metabolism Disease

GO Terms for Phosphorus Metabolism Disease

Cellular components related to Phosphorus Metabolism Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.65 GALNT3 GNAS PHEX SLC34A1 STX16
2 vesicle GO:0031982 9.5 SLC34A1 SLC34A2 SLC34A3
3 brush border GO:0005903 9.33 SLC34A1 SLC34A2 SLC34A3
4 brush border membrane GO:0031526 9.13 SLC34A1 SLC34A2 SLC34A3
5 apical plasma membrane GO:0016324 9.1 CASR GNAS KL SLC34A1 SLC34A2 SLC34A3

Biological processes related to Phosphorus Metabolism Disease according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.88 FAM20C FGF23 SLC34A1 SLC34A2
2 calcium ion transport GO:0006816 9.81 CYP27B1 PTH VDR
3 sodium ion transport GO:0006814 9.8 SLC34A1 SLC34A2 SLC34A3
4 cellular calcium ion homeostasis GO:0006874 9.77 CASR PTH VDR
5 fibroblast growth factor receptor signaling pathway GO:0008543 9.77 FGF23 GALNT3 KL
6 skeletal system development GO:0001501 9.77 FAM20C GNAS PHEX PTH VDR
7 bone mineralization GO:0030282 9.72 CYP27B1 PHEX PTH
8 positive regulation of bone mineralization GO:0030501 9.69 FAM20C KL PTH
9 response to vitamin D GO:0033280 9.67 CYP27B1 PHEX PTH
10 calcium ion homeostasis GO:0055074 9.65 CYP27B1 KL
11 response to cadmium ion GO:0046686 9.65 PTH SLC34A1
12 decidualization GO:0046697 9.65 CYP27B1 VDR
13 vitamin D metabolic process GO:0042359 9.65 CYP27B1 FGF23 VDR
14 regulation of bone mineralization GO:0030500 9.64 CYP27B1 FGF23
15 response to lead ion GO:0010288 9.63 PTH SLC34A1
16 cellular response to vitamin D GO:0071305 9.63 CASR FGF23 PHEX
17 energy reserve metabolic process GO:0006112 9.62 GNAS KL
18 positive regulation of keratinocyte differentiation GO:0045618 9.62 CYP27B1 VDR
19 response to growth hormone GO:0060416 9.61 PHEX SLC34A1
20 response to magnesium ion GO:0032026 9.61 FGF23 SLC34A1
21 phosphate ion transport GO:0006817 9.61 SLC34A1 SLC34A2 SLC34A3
22 response to fibroblast growth factor GO:0071774 9.58 CASR PTH
23 cellular response to parathyroid hormone stimulus GO:0071374 9.58 FGF23 PHEX SLC34A1
24 dentinogenesis GO:0097187 9.57 FAM20C SLC34A1
25 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.56 FGF23 KL
26 response to sodium phosphate GO:1904383 9.54 FGF23 PHEX
27 vitamin D catabolic process GO:0042369 9.52 CYP27B1 FGF23
28 phosphate ion homeostasis GO:0055062 9.5 FGF23 PTH SLC34A1
29 sodium-dependent phosphate transport GO:0044341 9.43 SLC34A1 SLC34A2 SLC34A3
30 response to parathyroid hormone GO:0071107 9.33 GNAS PTH SLC34A1
31 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.13 CYP27B1 FGF23 VDR
32 cellular phosphate ion homeostasis GO:0030643 8.92 FGF23 SLC34A1 SLC34A2 SLC34A3

Molecular functions related to Phosphorus Metabolism Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 symporter activity GO:0015293 9.43 SLC34A1 SLC34A2 SLC34A3
2 fibroblast growth factor receptor binding GO:0005104 9.32 FGF23 KL
3 vitamin D binding GO:0005499 9.16 KL VDR
4 sodium:phosphate symporter activity GO:0005436 9.13 SLC34A1 SLC34A2 SLC34A3
5 sodium-dependent phosphate transmembrane transporter activity GO:0015321 8.8 SLC34A1 SLC34A2 SLC34A3

Sources for Phosphorus Metabolism Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....